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Since newborn screening (NBS) began in the 1960s, technological advances have enabled its
expansion to include an increasing number of disorders. Recent developments now make it
possible to sequence an infant’s genome relatively quickly and economically. Clinical ap-
plication of whole-exome and whole-genome sequencing is expanding at a rapid pace but
presents many challenges. Its utility in NBS has yet to be demonstrated and its application in
the pediatric population requires examination, not only for potential clinical benefits, but
also for the unique ethical challenges it presents.
Newborn screening (NBS) in the UnitedStates began in the 1960s, shortly after the
publication of Robert Guthrie’s paper describ-
ing a method for detecting phenylketonuria
(PKU) in dried blood spots through a bacterial
inhibition assay (Guthrie and Susi 1963). It has
been defined as a public health activity aimed
at the early identification of infants who are
affected by certain genetic, metabolic, or infec-
tious conditions (AAP Committee on Bioethics
2001) for which treatment can prevent unfavor-
able health outcomes. Millions of lives have
been saved and significant morbidities prevent-
ed through universal NBS in the United States
and other countries. Although a public health
success, expansion of NBS has often been driven
by technological advances as well as by pressure
from the public and special interest groups.
Rapid increases in the number of known genetic
and metabolic conditions and improved meth-
odologies have led to expansion of candidate
disorders for screening. Technological advances
have been closely intertwined with the ability to
screen for conditions, for example, the adapta-
tion of tandem mass spectrometry (MS/MS)
for detection and quantification of multiple an-
alytes in newborns’ blood spot samples (Mill-
ington et al. 1989).
Massively parallel sequencing (MPS, also
referred to as “next-generation sequencing” or
NGS) uses high-throughput sequencers that are
able to analyze DNA much more efficiently than
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previous methods such as Sanger sequencing.
This technology provides a new methodology
for screening and overcomes one of the major
barriers to adding conditions to recommended
newborn screening panels. Any number of con-
ditions for which there is a known genetic basis
can theoretically be screened for in an individ-
ual, potentially including the entire genome.
However, screening a newborn with genome-
scale sequencing raises significant complexities,
including the extent to which parents should
be able to learn about genetic predispositions
in a newborn, particularly conditions that may
not manifest clinically until adulthood, and in
many cases that may not have effective preven-
tive strategies. Children lack the autonomy of
adults, who can decide for themselves whether
to engage in genomic sequencing to determine
whether they have a gene mutation that predis-
poses them to a condition such as cancer. In
NBS, these decisions are made by and can di-
rectly impact the parents. This represents an
additional complication that requires special
consideration.
To ultimately determine the clinical utility
of genome-scale sequencing in NBS and to eval-
uate whether such an approach offers added val-
ue, it will be imperative to assess the sensitivity
and specificity of MPS for currently screened
conditions and whether sequencing can provide
diagnostic data as accurately as currently used
screening methods such as MS/MS. Will these
data significantly augment our ability to predict
disease prognosis and enable more targeted
management? What conditions would then
meet the criteria to be added to routine NBS
use? To answer these questions, it will be neces-
sary to study the yield of sequencing for com-
mon conditions detected by current NBS (e.g.,
PKU, medium-chain acyl-CoA dehydrogenase
deficiency [MCADD], cystic fibrosis [CF] and
hearing loss), as well as conditions that meet
criteria for NBS but were not possible to detect
owing to lack of an adequate screening method
(e.g., certain lysosomal storage disorders and
primary ciliary dyskinesia). The application of
sequencing in NBS will allow not only the delin-
eation of the causative mutation in the proxi-
mally causative gene, thus augmenting studies
of phenotype-genotype relationships, but it
could also create a valuable long-term resource
for researchers to investigate how currently un-
known loci contribute to clinical heterogeneity.
APPLICATION OF DNA SEQUENCING
IN NEWBORN SCREENING
Selection of Genes to Include in Sequencing-
Based Newborn Screening
As articulated by Wilson and Jungner: “The
central idea of early disease detection and treat-
ment is essentially simple. However, the path to
its successful achievement (on the one hand,
bringing to treatment those with previously un-
detected disease, and, on the other, avoiding
harm to those persons not in need of treatment)
is far from simple though sometimes it may
appear deceptively easy” (Wilson and Jungner
1968; Andermann et al. 2008). Introducing ge-
netic testing into screening programs in the past
was a relatively slow multistep process with pilot
screening programs undertaken after a disease
gene or method of identification for a disorder
was discovered, and experts agreed was reason-
able and efficacious to add to a panel (ACMG
Newborn Screening Expert Group 2006; Ander-
mann et al. 2008). Even with multiplex screen-
ing methodologies such as MS/MS that can
identify analytes associated with multiple in-
born errors of metabolism, pilot programs
were initiated by states before widespread vali-
dation (Frazier et al. 2006).
Currently, the Discretionary Advisory
Committee on Heritable Disorders in New-
borns and Children evaluates conditions nom-
inated for inclusion in NBS programs through a
comprehensive systematic evidenced-based re-





2013.pdf ) (Kemper et al. 2014). This review
process considers not only the magnitude and
certainty of net benefit, but also the capability of
states to implement comprehensive screening.
Twenty-three conditions were considered but
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not included in the original recommended uni-
form screening panel (RUSP) because they lack
an accurate screening method (ACMG Newborn
Screening Expert Group 2006); 21 of these are
detectable in some or all cases with molecu-
lar genetic analysis and, therefore, have the
potential to be added to NBS panels. However,
the rate at which new disease genes are being
identified outpaces the ability of professionals
and policy makers to assess the potential benefits
and pitfalls of introducing or expanding genetic
screening programs (Andermann et al. 2008),
and formal review of the estimated 3260 genes
with a human phenotype-causing mutation (see
http://omim.org/statistics/geneMap) would
be a daunting task. Ultimately, it will be neces-
sary to construct a list of genes associated with
conditions that are part of the current RUSP as
well as those that are deemed to fulfill criteria for
NBS and are detectable by sequencing. This pan-
el would include conditions with onset in child-
hood in which early identification could allow
prevention or amelioration of symptoms. The
process will also need to include a mechanism
for updating the list to reflect advances in med-
ical genetics. Figure 1 depicts a timeline of ad-
vances in technology and newborn screening.
Incorporating Sequencing into Routine
NBS Practice
Several challenges must be met to effectively in-
corporate sequencing into NBS. First, the tech-
































of children with severe
intellectual disability
1962: Massachusetts department of
public health begins NBS for PKU
1970′s: Congenital hypothyroidism,
Sickle cell disease, 21-hydroxylase
deficiency, galactosemia
1990′s: MS/MS allows expansion of
disorders screened but not
implemented uniformly
2006: ACMG workgroup recommends
29 “core conditions” and 25 “secondary
targets” for universal NBS
Genome-scale sequencing
permits potential screening of






Figure 1. Milestones in newborn screening are depicted in the lower portion of the figure, with approximate
dates on the horizontal axis. The number of conditions screened for (or potentially screened for) is depicted
chronologically with asterisks on the vertical axis, plotted on a logarithmic scale. Screening programs have
historically differed between states, most dramatically observed after development of tandem mass-spectrometry
technology in the 1990s. Adoption of a recommended uniform screening panel in 2005–2006 has gradually led
to greater consistency. Development of next-generation sequencing technology in the early 2000s, with subse-
quent reduction in the cost of genome-scale sequencing, makes it possible to analyze thousands of disease genes.
The number of conditions potentially screened for is indicated with a question mark to emphasize the sub-
stantial concerns regarding the application of such technology in healthy newborns.
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comparison to standard NBS methods. Next,
thoughtful choices must be made about whether
to include conditions that are not amenable to
current screening methods, yet, would other-
wise meet criteria for screening in a public health
setting versus others that would be reasonable
candidates if accompanied by more rigorous in-
formed parental consent. Finally, any serious
proposal to supplement traditional NBS by ge-
nome-scale sequencing demands careful con-
sideration of the optimal clinical setting in
which parents learn about the series of complex
decisions they would need to make to provide
informed consent and the methods by which
they are guided in this decision making process.
All 50 states in the United States currently
screen for a panel of conditions that include
hemoglobinopathies, disorders of amino acid,
fatty acid and organic acid metabolism, con-
genital hypothyroidism, congenital adrenal hy-
perplasia, galactosemia, biotinidase deficiency,
and cystic fibrosis. Thirty-four states also man-
date newborn hearing screening (see http://
genes-r-us.uthscsa.edu/sites/genes-r-us/files/
nbsdisorders.pdf ). In most states, NBS is man-
dated by state laws; only a few states consider
it voluntary and require specific parental con-
sent (Seashore and Seashore 2005). The public
health benefits and importance of NBS must be
weighed against the rights of parents to make
decisions about their child. Some have ar-
gued that preventive programs conducted un-
der public health auspices should be held to the
same ethical standards as medical innovations
introduced into the private sector (Skrabanek
1990). Some have proposed screening for all but
a selected group of conditions, whereas others
point out the potential for a “treatment odys-
sey” undertaken by families whose child is iden-
tified with a serious condition through screen-
ing for which no effective treatment exists (Baily
and Murray 2008; Bailey et al. 2008). Although
there is strong support for universal screening
for disorders in which early diagnosis and treat-
ment is lifesaving or produces great medical
benefit, justifying the omission of explicit in-
formed consent, this will not be the case for
many new conditions that will be identifiable
through sequencing. Available interventions
for these disorders may have varying efficacy,
and many disorders could have pleiotropic ef-
fects. Incorporation of genetic sequencing pan-
els or even genome-scale sequencing into the
NBS paradigm raises significant concerns about
the management of such information (Bailey
et al. 2008). Conditions that are clinically signif-
icant and may benefit patients greatly by surveil-
lance and early diagnosis of complications, such
as familial adenomatous polyposis, could have
an equivalent impact to conditions that are cur-
rently screened. Conditions associated with de-
velopmental disability for which there may be
no “cure” but for which early intervention and
therapy services may be valuable are clearly dif-
ferent than those that have traditionally been
included in NBS programs; it would be difficult
to justify such screening being “mandatory,”
and thus parental informed decision-making
will be needed. As public health proponents an-
ticipate the use of NGS to improve health out-
comes, care must be taken not to undertake a
slippery slope of utilizing this technology with-
out rigorous scientific and ethical examination
of its utility, acceptance, and consequences.
Secondary Findings
If genome-scale sequencing ultimately becomes
the most cost-effective means of generating se-
quence data for NBS, the analysis could be fo-
cused on a subset of genes through the use of
informatics filters. However, whenever genome-
scale sequencing is performed, there will inevi-
tably be additional clinically significant variants
in genes that may not have been the original
intent of the screening. These additional find-
ings could be considered “incidental” or “sec-
ondary” findings; whether theyshould be part of
the routine analysis is a subject of intense de-
bate. The American College of Medical Genetics
and Genomics (ACMG) recommended that
when genome-scale sequencing is performed
in a diagnostic setting, known pathogenic or
expected pathogenic variants in 56 genes should
be reported back to patients unless they opt out
of receiving such findings (Green et al. 2013). In
general, the ACMG relied on the guiding prin-
ciple of clinical actionability to generate this list
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of genes, but the process did not use a systematic
approach and the resulting list has been criti-
cized (Burke et al. 2013; Ross et al. 2013a). The
list was also not developed specifically for chil-
dren, and indeed NBS conditions were excluded
from consideration. As a result, the list recom-
mended by the ACMG includes some condi-
tions that have onset in adulthood, such as he-
reditary breast and ovarian cancer susceptibility
caused by mutations in BRCA1 and BRCA2.
Should these conditions be included as part of
NBS when a genome-scale sequencing method
is used? Previous recommendations have ar-
gued against testing children for adult-onset
disorders, preferring to defer such testing until
the individual can decide whether he or she
wants to have that information (see section on
Ethical Considerations).
EXAMPLES OF CONDITIONS AMENABLE
TO AUGMENTED NEWBORN SCREENING
Phenylketonuria (PKU)
PKU is one of the most common inborn errors
of metabolism detected by NBS. It is awell-char-
acterized amino acid disorder caused by defi-
ciency of the liver enzyme, phenylalanine hy-
droxylase (PAH), leading to elevated levels of
the amino acid, phenylalanine (Phe) in blood
and other tissues. It is inherited in an autosomal
recessive pattern. Left untreated, PKU causes
severe to profound intellectual disability, micro-
cephaly, seizures, and behavior problems. It was
the first condition to be screened for in new-
borns and one in 15,000 infants is born in the
United States with classical PKU. Milder vari-
ants, known collectively as the hyperphenylala-
ninemias, result from partial deficiency of the
enzyme and occur in approximately one out of
48,000 births. PKU and hyperphenylalanene-
mia are currently detected through MS/MS
of dried blood spots and screen positive cases
are confirmed by measuring Phe levels in blood
samples. After confirmation, patients are imme-
diately placed on a diet that strictly controls
their intake of Phe and their Phe levels are close-
ly monitored. Dietary treatment must begin
within the first weeks of life and continue
throughout the patient’s lifetime. The amount
of protein restriction required to maintain nor-
mal blood Phe levels varies among patients. Use
of the cofactor tetrahydrobiopterin (BH4; Ku-
van) allows 50% of patients to increase their
protein intake thus approximating a more nor-
mal diet. The variable clinical course of PKU is,
in part, based on the specific mutations in the
gene encoding the L-phenylalanine hydroxylase
enzyme and the amount of Phe in the diet. More
than 400 mutations have been identified in the
PAH gene and show a broad spectrum of types
including deletions, insertions, missense, splic-
ing, and nonsense. Although there is a modest
correlation between genotype and the distinct
phenotypes of classical PKU and hyperphenyla-
lanenemia (Utz et al. 2012), there are other
contributing factors as evidenced by sibling dis-
cordance, especially in the response to treat-
ment, that is Phe restriction alone, with BH4
or with large neutral amino acids. A “genotype
severity” tool has been developed to study the
correlation of PAH mutation(s) with respon-
siveness to BH4 and its use has been recom-
mended to help define which patients will show
the best response. However, there is significant
overlap between patients of different genotypes
and precise predictions cannot be made before
a therapeutic trial with the cofactor (Quirk et al.
2012). Genes at other loci may influence Phe
transport within the brain as well as play a role
in other features of the clinical phenotype; these
modifier genes have been hypothesized to exist
but have not yet been identified. It has been
recommended that all patients with confirmed
PKU have mutation analysis for genotype deter-
mination (National Institutes of Health Con-
sensus Development Panel 2001). Information
about specific PAH mutations as well as varia-
tion in other relevant genes, obtained through
MPS, may help explain this phenotypic variabil-
ity. It may also improve treatment outcomes by
more targeted intervention and dietary regula-
tion of Phe levels.
Hearing Loss
Hearing loss is the most common birth defect
and the most prevalent sensorineural disorder
Genome-Scale Sequencing and Newborn Screening



















in developed countries (Hilgert et al. 2009). One
of every 500 newborns has bilateral permanent
sensorineural hearing loss that is greater or
equal to a 40 decibel loss. Early detection and
appropriate intervention results in improved
development of language, cognitive, and social
skills (White 2004). In 1993, a National Insti-
tutes of Health (NIH) consensus statement
recommended that all infants have hearing
screening shortly after birth (NIH 1993) and
guidelines were established in 2000 (Joint Com-
mittee on Infant Hearing 2000). Screening is
now performed in all states through Early Hear-
ing Detection and Intervention (EHDI) pro-
grams with either otoacoustic emission (OAE)
or automated auditory brainstem response
(AABR) methodology. In 2009, it was estimated
that 96.6% of newborns in the United States had
hearing screening (see www.cdc.gov/ncbddd/
hearingloss/ehdi-data2012.html).
Hearing loss represents a particularly prom-
ising avenue for realizing advances in NBS by
using genomic sequencing approaches. Approx-
imately 50% of prelingual deafness has a genetic
etiology, with 70% categorized as nonsyn-
dromic of which 75%–85% is autosomal reces-
sive, 15%–24% autosomal dominant, and 1%–
2% is X-linked or mitochondrial. Although
50% of autosomal recessive nonsyndromic
hearing loss is caused by mutations in genes
encoding the proteins connexin 26 or 30, 50%
is caused by mutations in at least 40 other genes.
Thirty percent of genetic prelingual hear-
ing loss is associated with syndromes (Smith
et al. 1993). Syndromic forms can have comor-
bid conditions including blindness, cardiac
arrhythmias, kidney disease, endocrine disor-
ders, and intellectual disability. In newborns,
phenotypic features of syndromic hearing loss
are usually not yet apparent, making targeted
gene testing impossible. Even many of the com-
mon syndromic forms of hearing loss show con-
siderable locus heterogeneity. One striking ex-
ample is Usher syndrome, a condition with
early onset deafness and retinitis pigmentosa
with progressive loss of vision in later child-
hood, for which 18 genes or loci have been
identified to date (see http://www.omim.org/
phenotypicSeries/276900). Testing for muta-
tions in these genes through standard sequenc-
ing is prohibitive because of cost and time. Not
knowing the etiology may contribute to the
stress reported in families after confirmation
of hearing loss in their child (Vohr et al. 2008).
Additionally, not all infants with significant ear-
ly-onset hearing loss will have positive newborn
screens (Young et al. 2011), thus preventing ear-
ly identification. Sequencing could potentially
detect mutations in all known syndromic and
nonsyndromic hearing loss genes, thus provid-
ing a specific diagnosis not only in infants with
a genetic cause of hearing loss detected through
NBS but also in those who would otherwise not
be identified through NBHS and thus provides
a method to expand the scope of NBS. In addi-
tion, its application would increase our knowl-
edge regarding genetic etiologies of hearing loss
that are currently poorly understood.
Additional Conditions
Of the 31 conditions in the current RUSP, 27
have identified genetic etiologies, whereas the
remaining four (congenital hypothyroidism,
hearing loss, critical congenital heart disease,
and severe combined immunodeficiencies) are
frequently because of identifiable genetic causes
(see Table 1). Although other screening meth-
ods remain more sensitive and economical, mo-
lecular analysis is being increasingly used for
confirmatory testing and to determine progno-
sis and appropriate treatment for many of these
conditions as well as for the 26 secondary dis-
orders detected in the differential diagnosis of
the core disorders in the RUSP (Carrillo-Carra-
sco and Venditti 1993; Manoli and Venditti
1993; Bhardwaj et al. 2005; Collins et al. 2010;
Bhattacharjee et al. 2014; Kwan et al. 2014).
There are a number of serious and treatable
childhood conditions that are not currently
screened for lack of an effective test. MPS has
the potential to identify the molecular basis for
disorders currently included on NBS panels,
but, more importantly, it could significantly ex-
pand our ability to detect a much broader range
of genetic conditions. Some conditions were
considered as candidates for screening by the
expert panel convened by the ACMG in 2002
J.S. Berg and C.M. Powell
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and despite being ranked highly in terms of their
clinical significance, availability and efficacy of
treatments and potential for avoidance of seri-
ous sequelae through early detection, could not
be added to the recommended panel due to
lack of an available screening test. Many have
an underlying genetic etiology, with the causa-
tive genes identified and, therefore, could be
detected through molecular techniques. In the
list of 23 conditions not included in the recom-
mended screening panel because they lack an
accurate screening method (ACMG Newborn
Screening Expert Group 2006), 21 are detectable
in some or all cases with molecular genetic anal-
ysis and, therefore, have the potential to be add-
ed to NBS panels (see Table 1). Of 52 types of
inborn errors of metabolism considered for in-
clusion in recommended NBS panels, all have
the potential for detection with sequencing.
These include Fabry disease, familial hypercho-
lesterolemia, Wilson disease and the Creatine
Deficiency Syndromes that cannot be detected
with standard NBS methods.
Sequencing offers the ability to expand this
list beyond inborn errors of metabolism. The
list could include, for example, genes associated
with early childhood cancer such as multiple
endocrine neoplasia type IIB due to mutations
in the RET gene, inherited channelopathies that
lead to potentially preventable cardiac arrhyth-
mias, and primary ciliary dyskinesia (PCD), a
rare, genetically heterogeneous disorder result-
ing in a range of manifestations including situs
inversus, neonatal respiratory distress at full-
term birth, recurrent otitis media, chronic si-
nusitis, chronic bronchitis that may result in
bronchiectasis, and male infertility.
Other conditions have not been included in
recommended screening panels due to lack of
treatment by traditional definitions. Individu-
als with conditions leading to intellectual dis-
ability might derive benefit from early detection
and intervention, including earlier enrollment
in developmental intervention services and
avoidance of the diagnostic odyssey. In 2006,
Alexander and van Dyck challenged the tradi-
tionally held belief that NBS should only in-
clude conditions with effective treatments and
broadened the concept to include conditions
with benefits to the family for reproductive de-
cision making, the potential to participate in
research or innovative therapeutics and avoid-
ance of the diagnostic odyssey (Alexander and
van Dyck 2006). On the other hand, genetic
information predicting the inevitable develop-
ment of an incurable genetic disorder may be
unwelcome to some parents of otherwise appar-
ently healthy newborns. The practice of manda-
tory screening for such nonmedically actionable
conditions, if widely accepted by public health
screening programs, would dramatically alter
the nature of the screening program, potentially
undermining the currently accepted practice of
screening without obtaining explicit consent.
ETHICAL CONSIDERATIONS
Unlike many kinds of medical tests, which pro-
vide information of a transient, temporal na-
ture, genetic testing typically can reveal infor-
mation about an individual’s past, present, and
future medical conditions; this information
may also have immediate implications for fam-
ily members. These characteristics, combined
with the complexity of genetic information,
which ranges from probabilistic to highly deter-
ministic, has led many to view genetic informa-
tion as somehow different from other kinds of
biomedical information (“genetic exceptional-
ism”). Consideration of the ethical, legal, and
social implications of genetic knowledge has
been an inherent component of the Human
Genome Project and other genomic research
efforts (Greely 1998), and inexorable advances
in genetic testing have been accompanied by an
immense societal discussion about the most ap-
propriate uses of this information in healthcare,
in human subjects research, and even in the
setting of personal genomic exploration (Bun-
nik et al. 2011). The thread of an individual’s
right to self-determination is woven tightly
throughout the ethical considerations of genetic
testing (e.g., Nyrhinen et al. 2009; Bunnik et al.
2013). Genetic testing in children raises addi-
tional complexities that could potentially alter
the dynamic that currently exists in NBS.
Considerations of the benefits and risks of
genetic testing are perhaps most acute in chil-
J.S. Berg and C.M. Powell



















dren because of their special status as minors,
under the guardianship of their parents for a
period of time, after which they may achieve
independence and acquire their own right to
self-determination (Lantos 2010). Although
parents are given a significant amount of leeway
in their decisions about how to raise their chil-
dren, there are also limits on this guardianship
regarding that child’s future autonomy. Parents
have the responsibility to act in their child’s best
interests, which is the primary consideration in
most approaches to pediatric genetic testing.
Further complicating matters, consideration of
such testing inevitably occurs in the context of
highly variable childhood developmental states
and unique family settings (Fanos 1997).
Expert panels have put forth various guide-
lines to delineate appropriate uses of genetic
testing in children (Wertz et al. 1994; ASHG
Board of Directors, ACMG Board of Directors
1995; AAP Committee on Bioethics 2001; Ross
et al. 2013b). These recommendations have tra-
ditionally been grounded in “best interests”
being limited strictly to the impact of genetic
information for the child in question. For ex-
ample, it is generally agreed that testing children
for adult-onset conditions should be avoided
when the information would not directly im-
pact medical management during childhood.
This recommendation typically envisions the
scenario in which a condition is known to exist
in a family and the at-risk child will be able to
make an informed decision about genetic test-
ing when they reach adulthood. The recom-
mendation to avoid predictive genetic testing
is based in the idea that such testing will not
alter medical management of the child, and
that there could be psychological harms associ-
ated with learning one’s mutation status. The
ACMG recommendations regarding the return
of adult-onset clinically actionable incidental
findings in children (Green et al. 2013) appears
to be at odds with these restrictions on testing
for adult-onset disorders, except that in the case
of a child undergoing diagnostic genome-scale
sequencing or NBS, there may be no knowledge
in the family about a clinically actionable adult-
onset disorder (e.g., a 25-year-old mother with
no family history of early-onset breast cancer
who inherited a BRCA1 mutation from her fa-
ther). Such a finding, if not reported, could lead
to irreparable harm to the child caused by the
early death of a parent from a condition that
might have been prevented. This type of inci-
dental finding could therefore have direct psy-
chological benefit to the child and be in the
“best interests of the child,” even though the
revelation of the information may obviate that
child’s “right not to know” later in life. Howev-
er, opinion seems to be split regarding the jus-
tification of revealing information about adult-
onset clinically actionable conditions in a child
when the benefits are theoretical and less certain
to accrue than the discovery of a condition with
direct medical implications for the child (e.g.,
Strong et al. 2014; Yu et al. 2014). Clearly, there
is equipoise about the balance of benefits and
harms in this situation. There is a view that
testing for carrier status for recessive disorders
is not likely to benefit the child and should thus
be deferred until the individual is considering
reproduction. However, it should be noted that
substantial counter arguments have been made
on behalf of informed decision making by par-
ents, despite these concerns (Pelias 2006; Rho-
des 2006).
In the recommendations made by the
ACMG and AAP regarding the uniform screen-
ing panel (ACMG Newborn Screening Expert
Group 2006), the expert group made three rec-
ommendations that could have profound impli-
cations for NBS via genome-scale sequencing.
First, the expert group recommended that
25 additional “secondary” targets be examined
and reported. Although the original intent of
NBS was to detect only the specific condition
screened for, such as PKU, it has long been rec-
ognizedthat somewithpositivenewbornscreens
had less medicallysignificant conditions, such as
hyperphenylalaninemia, raising concerns that
this would cause some children to undergo un-
necessary treatments and cause parents undue
anxiety (Gurian et al. 2006). These 25 conditions
are “clinically significant and revealed by the
screening technology but lack an efficacious
treatment” and the expert group “thought it
was important that such findings be communi-
cated to the health care service community and
Genome-Scale Sequencing and Newborn Screening



















to families” (ACMG Newborn Screening Expert
Group 2006). The direct implication of this rec-
ommendation is that any clinically relevant find-
ing from NBS should be reported, which in the
case of genome-scale sequencing would include
essentially any genetic condition. Presumably,
the expert group was not envisioning the use of
a genome-scale sequencing test for NBS when
they made these recommendations, because
many families would refuse such testing if
they knew there was a possibility of learning
about findings without any related preventive
measures (Bombard et al. 2014), thus jeopar-
dizing the immense value of the newborn
screen at the population level.
Second, the expert group recommended
that states “mandate . . . reporting of any abnor-
mal results that may be associated with clini-
cally significant conditions, including the defin-
itive identification of carrier status” (ACMG
Newborn Screening Expert Group 2006). In
practice, carrier results for cystic fibrosis and
sickle cell disease are routinely returned as part
of NBS. Expanding this recommendation for
all conditions detectable by genome-scale se-
quencing would essentially convert NBS from
a program that detects rare, preventable dis-
orders in a small minority of cases into a carrier
screening test for all recessive disorders that
would yield a handful of findings in every indi-
vidual screened. Again, the expert group was
likely not considering the implications of this
recommendation for genome-scale sequencing
being used in NBS.
Finally, the expert group recommended
that states “consider that the range of benefits
realized by NBS includes treatments that go
beyond an infant’s mortality and morbidity”
(ACMG Newborn Screening Expert Group
2006), which seems to imply that there is value
to NBS beyond preventable conditions—That
personal utility (or utility as perceived by the
family unit) is just as valid a consideration in
determining what information to divulge as the
traditional values of improving the health of
the individual child. This recommendation is
somewhat similar to the ACMG incidental
findings recommendations, in which the bene-
fit to the child is indirect and related to the
overall well-being of the child’s family mem-
bers. That being said, the expert group’s recom-
mendation, if taken to the logical extreme,
could be interpreted as meaning that any ge-
netic information that is desired by the parents
is justifiable if considered beneficial by the par-
ents.
Most would likely agree that when genetic
information is available, parents should have
a reasonable ability to learn such information
if desired, and also to refuse information that
they do not want. The challenge is in defining
what is “reasonable”—Herein lies the equipoise
when considering the use of genome-scale se-
quencing in NBS. It can be argued that parental
prerogative is the primary consideration—Par-
ents are responsible for their child’s health care,
and learning (or refusing) information about
any genetic condition could be considered
part of this responsibility. On the other hand,
some information could have damaging effects
on the child’s own well-being if that knowledge
interferes with parental bonding, creates family
stress including divorce, or leads to abuse or
abandonment. In addition, even the decision
making process could lead to strife between par-
ents if they are unable to agree about whether or
not to learn such information.
The mainstream consensus of the bioethics
community appears to be that adult-onset dis-
orders with no effective prevention or treatment
should be off-limits to parents and are most
appropriate for informed decision-making by
the individual when he or she becomes an adult.
That being said, some argue that even these dis-
orders fall within a parent’s responsibility to
raise their child to the best of their ability and
prepare them for any eventuality, that the theo-
retical harms are less significant than initially
supposed (Malpas 2008) and that parents are
in the best position to make decisions relative
to their child’s best interests (Robertson and
Savulescu 2001). Furthermore, in the case of a
disabled child who will likely never be able to
make an informed decision, parents could rea-
sonably expect to make such decisions on that
child’s behalf.
Clearly, the application of genome-scale se-
quencing in NBS raises a host of ethical, legal,
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and social implications (Tarini and Goldenberg
2012). Challenges related to the use of genomic
sequencing in newborns, both technical and
ethical, will need to be overcome to establish a
widely accepted NGS-based platform to aug-
ment NBS.
CONCLUSION
The possibility of a significant expansion of NBS
raises a numberof concerns, including the lackof
evidence-based efficacy studies, the need for in-
formed consent, the challenge of providing in-
formation and support for families, and the eth-
ical, legal, and social issues associated with such
scenarios as disclosure of carrier status or genetic
susceptibility to future disease (Taylor and Wil-
fond 2004; Botkin 2005; Baileyet al. 2006). There
are major objectives that need to be addressed to
incorporate use of genomics and other techno-
logical advances in NBS. Public and professional
education will be required, and the expert infra-
structure for dealing with children who screen
positive will need to be improved significantly
(Alexander and van Dyck 2006). Some consid-
eration should be given to whether the long-held
criteria for screening should be changed, by
broadening the concept of benefit from screen-
ing for the child to include the family.
With these challenges in mind, pilot pro-
jects to examine these issues are being funded
by the Eunice Kennedy Shriver National Insti-
tute of Child Health and Human Development
(NICHD) and the National Human Genome
Research Institute (NHGRI) of the National In-
stitutes of Health (NIH) under the Genomic
Sequencing and Newborn Screening Disorders
research program. Use of genome-scale se-
quencing in NBS will require careful consider-
ation and informed decision making by parents
and education of providers as they use this tech-
nology.
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